Infinium PharmachemShare price, financial results, shareholding and management

NSE Emerge · INFINIUMIodine chemicalsListed 17 April 2023
infiniumpharmachem.com ↗Live price on NSE ↗ISIN INE0MRE01011 · Lot 500 shares · ₹1.49 lakh
₹298.00
-3.50% on the day
Close · 19 Nov 2026
Valuation
Market cap
₹464 cr
Stock P/E
33.2peers 15.1
Book value
₹77.6
Price to book
3.84
EV / operating profit
19.8
Market cap to sales
2.44
Returns and growth
ROCE · FY26
14.9%
ROE · FY26
12.1%
ROE, 3-year average
17.1%
Operating margin · FY26
11.0%peers 8.9%
Sales growth, 3 years
18.6%
Profit growth, 3 years
11.9%
Safety
Debt to equity
0.00peers 0.48
Borrowings
₹0 cr
Interest cover
7.0×
Cash from business / op. profit
155%
Debtor days
60
Pledged
0.00%
Ownership and share
Promoter holding
64.91%
Change in promoter holding
+5.00 pts
Shareholders
1,061
52-week high / low
₹325 / ₹189
Dividend yield
0.00%
Face value
₹10

Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.

Infinium Pharmachem share price chart

₹298.00+21.88% 1 year

Close on 19 Nov 2026 · -3.53% on the day · Vol 7,500

Daily prices to 19 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.

Share price returns

To the close of 19 Nov 2026

1 month
+1.1%
3 months
+35.5%
6 months
+41.3%
1 year
+21.9%
Traded a day, 20 days
₹0.23 cr
Taken for delivery
92%

Business growth

Sales and net profit, from the reported results

SalesProfit
FY26 on FY25+22%+72%
3 years, a year+19%+12%
Latest half, H2 FY26+45%+167%

About Infinium Pharmachem: business, products and customers

Infinium Pharmachem makes chemicals from iodine that drug companies use to make medicines, and has started making raw materials for the dyes used in medical scans. Its plant is in Gujarat and its shares trade on NSE Emerge.

The company was formed in 2003 at Anand, Gujarat, and makes more than 220 iodine derivatives and 19 active pharmaceutical ingredients at GIDC Sojitra. Much of the work is made to order under confidentiality agreements for drug makers, a contract research and manufacturing model, and the company has named Sun Pharma, Dr. Reddy's, Glenmark, Neuland and Hetero Drugs among its customers. China and Japan are its main markets abroad, and an exclusive five-year distribution deal with K Sakai & Company covers Japan.

Iodine is all imported and makes up about 52% to 60% of what the company spends on materials, so its margin is the spread between the iodine price and what customers pay for the finished derivative. The group figures also include Infinium Healthcare, a 51% held company that trades pharma raw materials, and Shanghai Tajilin, a 51% held distributor in China, which is why consolidated sales are larger than the plant's own. The plant can make far more than it does, so higher volume would spread fixed costs over more tonnes.

Read more about the business

In January 2026 the company commissioned a new unit at Sojitra to make raw materials for contrast media, the iodine based dyes injected before X-ray and CT scans, including a compound called ATIPA. Through Infinium Healthcare it has a joint venture with IBL Elements in Texas to extract iodine from oilfield brine, from which it expects to take about 120 tonnes a year once production starts.

Management has named Samrat Pharmachem as the one listed company making iodine derivatives in India, with Calibre and G. Amphray among other makers. Blue Jet Healthcare, also listed, makes contrast media intermediates; management has said Infinium aims to supply contrast media raw materials rather than the contrast media drugs themselves.

From the offer document, the annual report for FY26, the investor presentation of November 2025, the results calls of March and June 2024 and the press release of January 2026.

Read the deeper study ↓

In its favour

  • It brings in more cash than it shows as profit: ₹34 cr against ₹14 cr in FY26.
  • It has little debt for its size: debt to equity 0.00.
  • The promoters own a large part of the company: 64.91%.

To watch

  • Sales from the contrast media unit started in January 2026, aimed at about ₹100 cr a year within three years (Press release, 16 January 2026, p.2).
  • Start of iodine supply from the Texas joint venture, expected by December 2026 (Investor presentation, November 2025, p.15).
  • Whether the largest customer's share of sales keeps rising (Annual report FY26, p.75).
  • Environmental compliance at Sojitra after the 2026 closure order (Annual report FY26, p.63).
  • The promoters' share has come down: 64.91%, from 73.05%.

From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.

Infinium Pharmachem revenue and profit growth

Half-yearly results · Profit and loss

Sales have grown steadily. Last year profit grew faster than sales, so the company kept more from each rupee of sales.

Sales and net profit, every year, ₹ crore
SalesNet profit
050100150200Sales, FY20: 39 ₹ cr39Net profit, FY20: 1 ₹ cr1FY20Sales, FY21: 71 ₹ cr71Net profit, FY21: 3 ₹ cr3FY21Sales, FY22: 99 ₹ cr99Net profit, FY22: 7 ₹ cr7FY22Sales, FY23: 114 ₹ cr114Net profit, FY23: 10 ₹ cr10FY23Sales, FY24: 136 ₹ cr136Net profit, FY24: 12 ₹ cr12FY24Sales, FY25: 156 ₹ cr156Net profit, FY25: 8.2 ₹ cr8.2FY25Sales, FY26: 190 ₹ cr190Net profit, FY26: 14 ₹ cr14FY26
The latest halves, ₹ crore
SalesNet profit
050100150Sales, H1FY23: 79 ₹ cr79Net profit, H1FY23: 6 ₹ cr6H1FY23Sales, H1FY24: 61 ₹ cr61Net profit, H1FY24: 6 ₹ cr6H1FY24Sales, H2FY24: 74 ₹ cr74Net profit, H2FY24: 5 ₹ cr5H2FY24Sales, H1FY25: 83 ₹ cr83Net profit, H1FY25: 5 ₹ cr5H1FY25Sales, H2FY25: 73 ₹ cr73Net profit, H2FY25: 3 ₹ cr3H2FY25Sales, H1FY26: 84.1 ₹ cr84.1Net profit, H1FY26: 5.6 ₹ cr5.6H1FY26Sales, H2FY26: 106 ₹ cr106Net profit, H2FY26: 8 ₹ cr8H2FY26

SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.

Infinium Pharmachem half-yearly results

SME companies report every six months · ₹ crore

₹ crore · growth on the same half a year before
H1FY23H1FY24H2FY24H1FY25H2FY25H1FY26H2FY26
Sales796174837384.05106
Expenses715166756573.6194
Operating profit91088810.4411
OPM11.0%17.0%11.0%10.0%11.0%12.4%11.0%
Interest111221.561
Depreciation011221.552
Profit before tax887658.3310
Net profit665535.608

Infinium Pharmachem profit and loss

Full years to March, FY20 to FY26 · ₹ crore, consolidated where reported

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Sales397199114136155.71190
Expenses36668998117139.29168
Operating profit2510161916.4222
OPM6.0%7.0%10.0%14.0%14.0%10.6%11.0%
Other income111122.122
Interest112323.673
Depreciation111133.293
Exceptional and other items··1·-1··
Profit before tax149131511.5718
Tax rate0.0%25.0%22.2%23.1%20.0%29.6%22.2%
Net profit13710128.1514
EPS ₹4.6513.6030.559.308.125.607.80
Dividend payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.

Infinium Pharmachem profitability

Margins and returns on capital

Last year the company kept about as much from each rupee of sales as the year before. It earns a moderate return on the money it uses.

Operating margin, every year

Per cent of sales kept before interest, depreciation and tax

0%5%10%15%20%FY20: 6.0%6.0%FY20FY21: 7.0%7.0%FY21FY22: 10.0%10.0%FY22FY23: 14.0%14.0%FY23FY24: 14.0%14.0%FY24FY25: 10.6%10.6%FY25FY26: 11.0%11.0%FY26
Per cent
FY20FY21FY22FY23FY24FY25FY26
Operating margin6.0%7.0%10.0%14.0%14.0%10.6%11.0%
Tax rate0.0%25.0%22.2%23.1%20.0%29.6%22.2%
ROCE·32.3%40.7%36.8%28.1%13.2%14.9%
ROE·54.5%70.0%57.1%29.6%9.7%12.1%
Dividend payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Infinium Pharmachem debt and cash flow

Balance sheet · Cash flow · Working capital

The company's own money, its net worth, has grown. It has almost no borrowings. Last year the business brought in more cash than it showed as profit. Customers take about as long to pay as they did in FY24.

Its own money and its borrowings, ₹ crore
Net worthBorrowings
050100150Net worth, FY20: 4 ₹ cr4Borrowings, FY20: 9 ₹ cr9FY20Net worth, FY21: 7 ₹ cr7Borrowings, FY21: 11 ₹ cr11FY21Net worth, FY22: 13 ₹ cr13Borrowings, FY22: 23 ₹ cr23FY22Net worth, FY23: 22 ₹ cr22Borrowings, FY23: 29 ₹ cr29FY23Net worth, FY24: 59 ₹ cr59Borrowings, FY24: 11 ₹ cr11FY24Net worth, FY25: 109 ₹ cr109Borrowings, FY25: 51.9 ₹ cr51.9FY25Net worth, FY26: 121 ₹ cr121Borrowings, FY26: 0 ₹ cr0FY26
Cash from the business against net profit, ₹ crore
Cash from the businessNet profit
-40-2002040Cash from the business, FY20: 3 ₹ cr3Net profit, FY20: 1 ₹ cr1FY20Cash from the business, FY21: 7 ₹ cr7Net profit, FY21: 3 ₹ cr3FY21Cash from the business, FY22: 12 ₹ cr12Net profit, FY22: 7 ₹ cr7FY22Cash from the business, FY23: 9 ₹ cr9Net profit, FY23: 10 ₹ cr10FY23Cash from the business, FY24: -13 ₹ cr-13Net profit, FY24: 12 ₹ cr12FY24Cash from the business, FY25: -29.2 ₹ cr-29.2Net profit, FY25: 8.2 ₹ cr8.2FY25Cash from the business, FY26: 34 ₹ cr34Net profit, FY26: 14 ₹ cr14FY26

Bars below the line are cash going out.

Infinium Pharmachem balance sheet

At each 31 March · ₹ crore

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Equity capital11151415.5816
Reserves3612174593.88105
Net worth47132259109.46121
Borrowings91123291151.850
Other liabilities91623201537.0854
Total liabilities2234597185198.39175
Fixed assets454192024.1623
Capital work in progress0480018
Investments0000029.0229
Other assets1825475265144.21115
Receivables·····33.7531.46
Inventory·····44.2539.05
Cash·····34.8429.78
Trade payables·····12.394.07

Infinium Pharmachem cash flow

₹ crore

₹ crore
FY20FY21FY22FY23FY24FY25FY26
Cash from operations37129-13-29.1634
Cash from investing-1-5-7-5-4-27.21-7
Cash from financing-1-1-2-32379.29-32
Net cash flow1131622.92-5
Capital spending·····8.659.69

Working capital

Days

Days
FY20FY21FY22FY23FY24FY25FY26
Debtor days75595749557960
Inventory days846278898713796
Days payable82795631163810
Cash conversion cycle764378108126178146
Working capital days46122527969799

Infinium Pharmachem peers and competitors

Listed SME companies in the same industry

By sales, Infinium Pharmachem is number 4 of the 34 listed SME companies in pharmaceuticals & biotechnology.

Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.

CompanyMarket cap ₹ crP/ESales ₹ crProfit ₹ crOp. marginDebt/equity
Sat Kartar Life22012.92011712.0%0.03
Infinium Pharmachem46433.21901411.0%0.00
Zenith Drugs6817.21713.97.1%0.75
Mono Pharmacare1644.61660.42.4%1.79
Astonea Labs34168.114859.0%0.74
Influx Healthtech63230.814720.520.3%0.00
Jfl Life Sciences355.51316.48.9%0.47
Dipna Pharmachem113.512933.9%0.21
Trident Lifeline48125.31291922.0%0.73
Chandra Bhagat Pharma3210.511633.3%0.50
Quest Laboratories15410.31121516.3%0.08
Median of the 10 others11115.11395.78.9%0.48

Infinium Pharmachem shareholding pattern

Promoters, FIIs, DIIs, HNIs and small holders

The promoters own more than half the company, a little less than in the first filing shown. Big foreign and Indian funds own very little. The number of shareholders has grown a lot.

Promoters
64.91%
-8.14 pts since Sep 23
Foreign investors (FIIs)
0.00%
at Mar 25; not in the latest pattern
Indian institutions (DIIs)
0.21%
+0.21 pts since Sep 23
HNIs (over ₹2 lakh each)
18.08%
+8.49 pts since Sep 23
Small holders (up to ₹2 lakh)
13.88%
-0.49 pts since Sep 23
Companies and others
2.92%
-0.07 pts since Sep 23
Number of shareholders
1,061
646 in Sep 23

Infinium Pharmachem shareholding pattern

Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.

Sep 23Mar 24Sep 24Nov 24Mar 25Sep 25Mar 26
Promoters73.05%73.05%73.05%65.24%65.24%59.91%64.91%
Foreign investors (FIIs)0.00%0.00%0.00%-0.00%--
Indian institutions (DIIs)0.00%0.00%0.00%0.00%0.00%0.02%0.21%
HNIs (over ₹2 lakh each)9.59%10.19%9.73%9.65%18.02%23.02%18.08%
Small holders (up to ₹2 lakh)14.37%13.65%14.24%22.40%13.98%14.19%13.88%
Companies and others2.99%3.11%2.98%2.71%2.76%2.86%2.92%
Number of shareholders6467719479989581,0521,061

The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.

Infinium Pharmachem study: the business from its own documents

Read from 12 of the company's own documents

Infinium Pharmachem so far

From the company's own record

  1. 17 April 2023Listed on NSE Emerge
  2. 31 March 2026Promoters at 64.91%
  3. 3 Oct 2024Highest close since listing, ₹358.74

Infinium Pharmachem key facts from the filings

Each figure with the document it comes from

Largest customer
48.71%
Share of FY26 standalone revenue from the single largest customer, up from 43.04%; the top five gave 71.93%.Annual report FY26, p.75
Plant capacity
1,800 tonnes a year
Installed capacity for iodine derivatives, against 293 tonnes actually made, about a fifth of what the plant can do.Investor presentation, November 2025, p.5 and p.18
Iodine cost
52% to 60%
Share of total material buying spent on iodine, which India fully imports.Transcript, June 2024 call, p.10
Contrast media unit
16 January 2026
Date the new unit for contrast media raw materials started, after a planned finish of December 2025.Press release, 16 January 2026, p.2; Investor presentation, November 2025, p.13
Export sales
₹35.5 cr
Standalone exports in FY26, down from ₹38.6 cr in FY25, while domestic sales rose.Annual report FY26, p.75
Show 5 more facts
Plant closure
13 April to 20 May 2026
The Gujarat Pollution Control Board ordered the Sojitra plant shut over alleged environmental lapses, then revoked the order; the company says it served demand from stock.Annual report FY26, p.21 and p.63
EU approvals
16 products
Products registered under EU REACH, with one more pending; FDA India also approved making APIs at the existing plant.Investor presentation, November 2025, p.12 and p.20
Japan distributor
5 years
K Sakai & Company will market all its iodine derivatives in Japan exclusively for five years.Investor presentation, November 2025, p.20
Iodine from Texas
About 120 tonnes a year
Iodine the company expects to take from the IBL Elements joint venture under a 30-year supply agreement; production was expected by December 2026.Investor presentation, November 2025, p.14 to 15
Credit rating
ICRA BBB (Stable)
First rating from ICRA, assigned in September 2026 on ₹52.2 cr of bank facilities.Credit rating letter, 21 September 2026, p.1 to 2

What the company said, and what happened

The company's own statements, attributed, set against what it later reported; not newboard's estimates

The company says it targets about ₹100 crore a year of revenue from contrast media raw materials within three years of the January 2026 start, at an EBITDA margin of about 30%, which it says would lift the blended margin to about 20%. Its November 2025 presentation spoke of sustainable revenue growth of 20% a year, a 14% share of its market in three to five years, and talks with two API makers for long term supply. It expected iodine from the Texas joint venture by December 2026.

₹100 crContrast media revenue aimWithin three years, January 2026
About 30%Contrast media EBITDA margin aimJanuary 2026
What management saidWhenWhat happened
Revenue of ₹200 cr in FY26Investor presentation, November 2025₹189.6 cr consolidated
Contrast media project complete in December 2025Investor presentation, November 2025Commissioned 16 January 2026

Is it a good business? Six questions

Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.

Infinium Pharmachem turns imported iodine into specialised chemicals that drug makers need, mostly made to order, and earns the spread between the two.

Its weak spots are dependence on one large customer, an iodine price it does not control, a plant that runs far below capacity, and a recent pollution board closure.

AverageCan it set its own prices?It keeps a fairly steady spread over iodine, but iodine is imported and its price is set abroad.
The evidence. The company says gross margin has stayed between 22% and 29% for five years, while iodine is 52% to 60% of material spending.Investor presentation, November 2025, p.5; Transcript, June 2024 call, p.10
AverageHow strong is it against rivals?Few companies make this range of iodine chemicals, but customers can turn to other makers and to imports.
The evidence. Management named one listed rival and a few small ones; the plant holds WHO-GMP and FDA India approval and 16 EU REACH registrations.Transcript, March 2024 call, p.9; Investor presentation, November 2025, p.12 and p.19
WatchWho are its customers?One customer gives about half of the plant's sales, and that share has been rising.
The evidence. The top customer gave 48.71% of FY26 standalone revenue against 43.04% a year earlier; the top five gave 71.93%.Annual report FY26, p.75
AverageDoes it need a lot of money?The main plant is built and has room to grow, but stock and dues have climbed and new projects needed fresh funds.
The evidence. Inventory rose from ₹24.7 cr in FY24 to ₹60.0 cr by September 2025 and receivables from ₹20.5 cr to ₹45.1 cr; cash from operations was negative in FY25.Investor presentation, November 2025, p.23 to 24
AverageCan it keep finding new work?New products, markets and a contrast media line give it ways to grow, but customer numbers have not grown lately.
The evidence. Customers fell from 332 in FY24 to 317 in FY25; the Japan distribution deal, FDA India API approval and contrast media unit are new.Investor presentation, November 2025, p.17 and p.20; Press release, 16 January 2026, p.2
WatchDo good and bad years swing a lot?Demand from drug makers is steady, but iodine prices, one big customer and plant approvals can move results sharply.
The evidence. EBITDA fell in FY25 as costs rose, and the plant was ordered shut for over a month in 2026 before the order was revoked.Investor presentation, November 2025, p.25; Annual report FY26, p.21

Who runs Infinium Pharmachem?

Promoters, directors and officers; tap a name for the background

SVSanjaykumar Viththalbhai PatelPromoter and Managing Director · holds 10.25%

Holds a master's degree from Gujarat University and has led the company's sales and marketing in India and abroad for about 20 years; a director since the company was formed and Managing Director from October 2022 to October 2027.

Offer document, p.148 and p.159; Shareholding pattern, March 2026
PBPravin Bhadabhai MadhaniPromoter and Executive Director · holds 21.66%

A graduate of Saurashtra University with a postgraduate degree from M. S. University, Vadodara and an LLB from Gujarat University. A director since the company was formed, in charge of production and regulatory matters, with 20 years of experience including three and a half years as a Mamlatdar with the Government of Gujarat.

Offer document, p.148 to 149 and p.159; Shareholding pattern, March 2026
MLMitesh Lavjibhai ChikhaliyaPromoter and Executive Director · holds 4.78%

Holds a master's degree in international business from Savitribai Phule Pune University; on the board since November 2010 and handles international business, finance and accounts. The offer document records Mitesh Lavjibhai Chikhaliya as a cousin of Sanjaykumar Viththalbhai Patel.

Offer document, p.148 to 149 and p.160; Shareholding pattern, March 2026
NPNilesh PatelExecutive Director (Finance)

A Company Secretary with LLB and B.Com degrees and 22 years in secretarial, finance and legal work, earlier with the GSPC Group and Torrent Power. Was CFO and Company Secretary until March 2026 and moved to Executive Director (Finance) from April 2026.

Investor presentation, November 2025, p.34; Announcement, 1 April 2026, p.1 to 2; Annual report FY26, p.3
KDKunj DesaiCompany Secretary, Compliance Officer and CFO

Took over as Company Secretary and CFO from 1 April 2026; the documents read give no further background.

Annual report FY26, p.3
KJKeyur Jagdishchandra ShahIndependent Director

A Company Secretary with an MBA in finance and a law degree, practising as an insolvency professional and registered valuer; on the board since October 2022.

Offer document, p.149; Investor presentation, November 2025, p.33
VAVaishakhi Ambrishbhai ShuklaIndependent Director

Holds a master's degree and a law degree with 15 years of experience in corporate matters and governance.

Investor presentation, November 2025, p.33

Infinium Pharmachem latest news and announcements

Announcements · Documents · Corporate actions

What changed recently

Each half-year is set against the same half a year earlier

  • H2 FY26: sales ₹106 cr (+45%), net profit ₹8 cr (+167%) on H2 FY25.
  • Shareholding, 31 March 2026: promoters 59.91% to 64.91%.

Infinium Pharmachem annual reports, earnings calls and documents

Every document links to its source; “read” marks those this page is built from

Infinium Pharmachem share split, bonus and dividends

From the corporate actions the company announces on the exchange

  • Bonus issueBONUS 1:1ex-date 13 Sept 2023
Checks we ran on Infinium Pharmachem's data · 10

Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.

  • !For FY26, H2FY25, H2FY26 the exchange filing's profit lines do not add up as read, so the figures shown are from the results page instead.
  • ✓Balance sheet totals add up for FY25 and FY26.
  • ✓Market cap uses the share count in the latest shareholding pattern (1,55,83,120 shares).
  • ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
  • ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
  • ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
  • ✓The two half-years of FY26 add up to the full-year sales.
  • !Earnings per share changes basis between FY22 (₹30.55) and FY23 (₹9.30) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
  • ✓Revenue and profit are reported for every year shown, FY20 to FY26.
  • iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.

Questions people ask about Infinium Pharmachem

What does Infinium Pharmachem do?

Infinium Pharmachem makes chemicals from iodine that drug companies use to make medicines, and has started making raw materials for the dyes used in medical scans. Its plant is in Gujarat and its shares trade on NSE Emerge.

What is the share price of Infinium Pharmachem?

₹298 at the close on 19 Nov 2026, from the exchange's daily figures.

What is the market cap of Infinium Pharmachem?

₹464 cr at the close on 19 Nov 2026, on 1,55,83,120 shares.

What is the P/E of Infinium Pharmachem?

33.2 times FY26 profit at the close on 19 Nov 2026 (our arithmetic).

What are Infinium Pharmachem's revenue and profit?

Revenue ₹190 cr and profit after tax ₹14 cr in FY26.

Who are the promoters of Infinium Pharmachem?

Sanjaykumar Viththalbhai Patel, Pravin Bhadabhai Madhani, Mitesh Lavjibhai Chikhaliya; promoters held 64.91% at 31 March 2026.

What is Infinium Pharmachem's website?

www.infiniumpharmachem.com

More SME companies like Infinium Pharmachem

Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.

Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2023 →

Built from 3 investor presentations, 2 earnings call transcripts, 2 annual reports, 2 credit rating notes, 1 offer document, 1 result filing, 1 press release, 59 exchange announcements, 7 shareholding patterns and 7 years of reported results. Every figure carries its source; where the documents are silent, the page says so.